Bad cholesterol slashed 62% by single dose of gene-editing drug in small trial

The interim Phase I trial data was only from 35 people, but results look good so far.

This news item is fetched from a public RSS feed. Title, summary, and image are © their respective publisher; follow the link above to read the full article on the original site.